Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

Chengfei Liu; Wei Lou; Joy C. Yang; Liangren Liu; Cameron M. Armstrong; Alan P. Lombard; Ruining Zhao; Onika D. V. Noel; Clifford G. Tepper; Hong-Wu Chen; Marc Dall’Era; Christopher P. Evans; Allen C. Gao

doi:10.1038/s41467-018-07178-x

Nature Communications (Nov 2018)

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer

Chengfei Liu,
Wei Lou,
Joy C. Yang,
Liangren Liu,
Cameron M. Armstrong,
Alan P. Lombard,
Ruining Zhao,
Onika D. V. Noel,
Clifford G. Tepper,
Hong-Wu Chen,
Marc Dall’Era,
Christopher P. Evans,
Allen C. Gao

Affiliations

Chengfei Liu: Department of Urology, University of California Davis
Wei Lou: Department of Urology, University of California Davis
Joy C. Yang: Department of Urology, University of California Davis
Liangren Liu: Department of Urology, West China Hospital, Sichuan University
Cameron M. Armstrong: Department of Urology, University of California Davis
Alan P. Lombard: Department of Urology, University of California Davis
Ruining Zhao: Department of Urology, General Hospital of Ningxia Medical University
Onika D. V. Noel: Department of Urology, University of California Davis
Clifford G. Tepper: Department of Biochemistry and Molecular Medicine, University of California Davis
Hong-Wu Chen: Department of Biochemistry and Molecular Medicine, University of California Davis
Marc Dall’Era: Department of Urology, University of California Davis
Christopher P. Evans: Department of Urology, University of California Davis
Allen C. Gao: Department of Urology, University of California Davis

DOI: https://doi.org/10.1038/s41467-018-07178-x
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 16

Abstract

Read online

The AR-V7 isoform is associated with anti-androgen drug resistance in prostate cancer. Here, the authors show that AR-V7 protein stability is regulated by HSP70/STUB1 complex-mediated proteostasis which confers drug resistance in late stage prostate cancer. Inhibition of HSP70 re-sensitizes resistant cells to enzalutamide therapy.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal